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INTRODUCTION 
Anemia is one of major contributing factor in maternal 
mortality and morbidity in third world countries and 
according to the WHO, contributes to 40% maternal 
deaths. Postpartum anemia is observed in up to 27% of 
women [1]. It is a common problem throughout the 
world [2]. It is a major cause of maternal morbidity such 
as lethargy, headaches, tiredness, dizziness, lactation 
failure, and postpartum depression and mortality in re-
source poor countries[3, 4] Depending on the grade of 
postpartum anemia, symptoms like reduced exercise 
performance, tiredness, headache, increased cardiovas-
cular strain, higher risk for infections, and lactation 
problems occur [5]. Iron deficiency is the principle 
cause of anemia [6]. Iron deficiency anemia is very 
much prevalent in the tropics particularly amongst 
women of child bearing age, especially in under privi-
leged sector. Nutrition of a woman in the family is al-
ways at bay because of various social and cultural prac-
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tices and on top of it she always remains in the dark 
about her own health. To highlight this, there is a saying 
in the countryside that ‘Gold is the metal she remembers 
and iron is the metal she forgets!’   
High prevalence of iron deficiency is attributable to 
faulty dietetic habit, faulty absorption mechanism be-
cause of high prevalence of intestinal infestation and 
increased iron loss as consequence of repeated pregnan-
cies at short intervals, excessive blood loss during men-
struation, hookworm infestation and chronic malaria [7]. 
Irrespective of mode of delivery, blood loss is a contrib-
uting factor. Majority of anemic women are received 
directly in labour without having any chance of correct-
ing anemia antenataly. Postpartum anemia is associated 
with longer hospital stays, depression, anxiety, and de-
layed infant development [8]. 
At the present time, there is no consensus on the man-
agement of postpartum anemia, and clinical practice 
varies from one clinic to another. The standard approach 
to treatment in the majority of institutions is oral supple-
mentation, with blood transfusion reserved for more 
severe or symptomatic cases [9]. There are number of 
hazards of blood transfusion including transfusion of 
wrong blood, anaphylaxis and infections, any of which 
would be devastating for the young mother [10]. Oral 
iron is unreliable in treatment of severe anemia due to 
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its limited absorption and gastrointestinal side effects 
that affect compliance [3]. Parenteral iron therapy by 
intramuscular injection of iron dextran is a painful alter-
native with a variable degree of efficacy. Because of its 
site of administration and side effects, compliance is 
low.  In practice the use of iron dextran is not generally 
recommended due to the unpredictable risk of life-
threatening or serious acute reactions in 0.6 to 2.3% of 
patients and the availability of safer agents [11-13]. Pa-
rental iron administration with ferrous sucrose is now 
available and can be used for treatment of iron deficien-
cy anemia in postpartum period [14]. 
This study was proposed to carry out a prospective ran-
domized study of intravenous iron sucrose in the treat-
ment of postpartum anemia. 
MATERIALS AND METHODS 
Study design:  An observational study.  
Ethics approval: The study was approved by the insti-
tutional ethics committee and informed consent was 
obtained from the participants.  
Study location: Department of Obstetrics and Gynae-
cology (OBGY) of Rural Medical College, Loni. 
Study period: Study was carried out over the period of 
2 years from 15th Sep 2016 to 14th June 2018. 
Inclusion criteria: Total 80 Women suffering from 
postpartum anaemia aged 18 years or more with Hemo-
globin of less than 10 g/dl but more than 6g/dl at 24 to 
48 hours after delivery who have treated with IV iron 
sucrose and those showing side effects to oral iron ther-
apy were included in the study after written informed 
consent.  
Exclusion criteria: Women who have received recent 
blood transfusion, Known cases of complications of 
pregnancy like eclampsia, heart disease etc where inten-
sive monitoring is required or any other medical/ surgi-
cal complications and those with known allergy to par-
enteral Iron Sucrose were excluded from the study. 
Methodology: 
After careful history taking, clinical examination and 
minimal investigations other causes of anemia were 
ruled out. The initial iron status of the woman was as-
sessed by the clinical and laboratory examinations 
(complete blood picture). The Haemoglobin (Hb) status 
of pregnant women who are clinically diagnosed with 
anemia was estimated by Sahli’s acid- haematin meth-
od. 2 ml of EDTA chelated blood from severely anae-
mic patients was sent for peripheral smear examination 
to the Central Lab, Rural medical hospital, Loni.  Mi-
crocytic, hypochromic appearance of RBCs confirm 
IDA. The Hb status of the patients confirmed with IDA 
was documented. 
Women having Hb levels less than 10 gm/dl at 24-48 
hours post-delivery were included in the study. They 
were administered intravenous iron sucrose 200 mg per 
dose per day till the total calculated dose was adminis-
tered.  
Iron sucrose was administered as an infusion in 250ml 
of 0.9% sodium chloride over a period of more than 30 
minutes. Patients were monitored for 30 minutes for 
signs of intolerance such as anaphylactic reactions, skin 
rash, dyspnoea, facial flushing, metallic taste, urtricaria, 
hypotension, headache, chest pain, tachycardia, breath-
lessness etc. The treatment was stopped after the admin-
istration of total calculated dose and received no further 
iron supplementation. The post therapy evaluation was 
done with the estimation of Hb on day 1, day 7, day 14 
and day 21.  
Statistical analysis - Data analysis was done by using 
appropriate statistical methods.  
RESULTS 
The maximum number of women 28(35%) belonged to 
the age group of 25-27 years. 31.25% women belonged 
to the age group each of 19-21 years and 22-24 years. 
Only 2 women (2.5%) were from age of 28 years. There 
were no women above 28 years of age (Table I). 
Table 1. Age distribution in study population 
 
Among 80 women, 44 (55%) women were delivered by 
FTND (full term normal vaginal delivery) while remain-
ing 36 (45%) women were delivered by LSCS (lower 
segment Caesarean section).(Table 2) 
Table 2. Mode of Delivery of Patients 
 
Maximum number of women reported blood loss in the 
range of 751-1000ml (55%) followed by 450-750ml 
(27.5%) and then 1001-1750ml (17.5%). (Table 3) 
Table 3. Amount of Blood Loss during and after de-
livery 
 
Maximum number of patients received 3 doses of IV 
Iron sucrose (i.e. total 600mg) followed by 2 doses (i.e. 
total 400mg), 4 doses (i.e. total 800mg) and 5 doses (i.e. 
total 1000mg) respectively (Table 4) 
Age (yrs) No. of women % 
19-21 25 31.25 
22-24 25 31.25 
25-27 28 35 
28 2 2.5 
Total 80 100 





FTND 44 55 
LSCS 36 45 





450-750 22 27.5 
751-1000 44 55 
1001-1750 14 17.5 
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Table 4. Total number of doses of IV Iron Sucrose 
administered 
 
Hb level rises extremely significantly (p<0.001) after IV 
Iron Sucrose administration on day 1, 7, 14 & 21 as 
compared to corresponding values before delivery as 
analyzed by Friedman Test (Nonparametric Repeated 
Measures ANOVA. Also Hb level rises extremely sig-
nificantly   (p<0.001) after IV Iron Sucrose administra-
tion on day 7, 14 & 21 as compared to corresponding 
values on Day 1 as analyzed by Friedman Test 
(Nonparametric Repeated Measures ANOVA). Howev-
er there is no statistically significant difference in Mean 
Hb values observed between Day 7 and Day 14 as well 
as between Day 7 and Day 21. Also, Mean Hb values 
between Day 14 & Day 21 did not differ significantly 
from each other. 
16 patients (20%) experienced thrombophlebitis to IV 
Iron Sucrose administration. About 12 (15%) patients 
experienced rigor followed by sweating in 10 patients 
(12.5%)  and fever in 8 patients (10%).4 patients (5%) 
suffered from nausea, 3 (3.75%) from vomiting and 2 
(2.5%) from flushing after IV Iron Sucrose administra-
tion. (Table 5) 
Table 5. Adverse effects reported to IV Iron Sucrose 
administration 
 
About 62 patients (77.5%) from total 80 reported well 
tolerability to IV Iron Sucrose while remaining 18 pa-
tients (22.5%) reported poor tolerability to IV Iron Su-
crose. (Table 6) 







Number of Patients 
(n=80) 
% 
2 25 31.25 
3 37 46.25 
4 14 17.5 
5 4 5 
Adverse Effects Number % 
Fever 8 10 
Rigors 12 15 
chest pain 0 0 
Dyspnoea 0 0 
Flushing 2 2.5 
Sweating 10 12.5 
Nausea 4 5 
Vomiting 3 3.75 
Thrombo-phlebitis 16 20 
Total 55 100 
Tolerability N (%) 
Well 62 (77.5%) 
Poor 18 (22.5%) 
DISCUSSION 
Iron deficiency anemia in pregnancy is a global public 
issue, affecting an estimated 41.8% of the pregnant 
women (Mclean et al 2008) [15]. It is associated with 
increased risk for low birth weight, preterm delivery, 
maternal and perinatal morbidity and mortality globally, 
especially in low resource settings [16, 17] 
Current UNICEF/WHO recommendations for the pre-
vention and treatment of anemia in pregnancy state that, 
where prevalence of anemia is <40%; mothers should 
receive 60 mg of iron plus 400μg of folic acid every day 
for 6 months in pregnancy and where prevalence is 
>40%; mothers should receive this  dose, continuing to 
3 months post partum.  
In the present study we investigated efficacy of IV Iron 
sucrose administration after comparing Hb values at 
different times and also found out the safety and tolera-
bility to IV Iron sucrose. 
While studying the distribution of anemia in various age 
groups in present study, the median age was 23 years. 
All study subjects were between 19-28 years (Table I). 
In some studies investigators had not found any signifi-
cant difference in the age on anemic and nonanemics 
women(Amy et al 2000, Geelhoed et al 2006) [18, 19] 
but one study had found significant difference of age in 
the studied population (Peterson et al) [20] where the 
mean age of anemic population was 25.8+5.6 (p value 
0.017). Women with less than 20 years of age were 
6.25% in the present study. Thus percentage of teenage 
pregnancy is low indicating that teenage pregnancy is 
showing a decreasing trend in our rural area.  When we 
compared our teenage pregnant population with the oth-
er study, the figures were much less compared to the 
other rural study population (Geelhoed et al) [19] in 
which 22.9% women were of age less than 20 with the 
mean Hb levels less than 8gm%. 
While comparing the mode of delivery in the present 
study, 44 (55%) patients included in the study had un-
dergone full term normal vaginal delivery while 36 
(45%) underwent casarean delivery.  During the litera-
ture search we could found no evidences to correlate 
maternal anemia and the mode of delivery.  
In our study, maximum number of women reported 
blood loss in the range of 751-1000ml (55%) followed 
by 450-750ml (27.5%) and then 1001-1750ml (17.5%) 
but none required blood transfusion as all three women 
were clinically and hemodynamically stable. All these 
women were managed with IV Iron sucrose administra-
tion. 
Iron sucrose is a high molecular weight complex of iron 
hydroxide with sucrose that on i.v. injection is taken up 
by RE cells, where iron dissociates and is utilized. It is 
safer than the older formulations and a dose of 100 mg 
(max 200 mg) can be injected i.v. taking 5 min, once 
daily to once weekly till the total calculated dose 
(including that to replenish stores) is administered. 
In our study, we have given IV Iron sucrose 200mg 
once daily to all patients till the total calculated dose 
was administered. The iron sucrose complex was ad-
ministered first and was diluted in 250 mL 0.9 % sodi-
um chloride, followed by 5 mL saline to flush iron parti-
cles from the tubing. The formula for calculating total 
Ashish et al.  Efficacy, tolerability and safety of intravenous iron sucrose in postpartum anaemia. 
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iron requirement is 
Iron requirement (mg) = 4.4 × body weight (kg) × Hb 
deficit (g/dl) 
Maximum number of patients received 3 doses of IV 
Iron sucrose (i.e. total 600mg) followed by 2 doses (i.e. 
total 400mg), 4 doses (i.e. total 800mg) and 5 doses (i.e. 
total 1000mg) respectively. 
Hb level rises extremely significantly (p<0.001) after IV 
Iron Sucrose administration on day 1, 7, 14 & 21 as 
compared to corresponding values before delivery as 
analyzed by Friedman Test. This indicated that maxi-
mum increase in Hb level occurred in first week while 
in second and third week, rise in Hb level is not that too 
fast as iron may be utilized to replenish the lost body 
stores. 
Study performed by Krafft et al [21] had also found 
efficacy of IV iron sucrose in patients of postpartum 
anemia. Hb level rises from baseline 7.5gm/dl to mean 
10.5gm/dl in 20 women after 15 days of IV iron sucrose 
administration. 
Safety analysis of IV iron sucrose administration re-
vealed that it was safer molecule as compared to earlier 
iron dextran and other compounds. No patient experi-
enced chest pain and dyspnoea while only 2 patients 
suffered from flushing which was common with Iron 
dextran and Iron Sorbitol citric acid. These results were 
highly encouraging for Gynaecologists and general 
practitioners as they can safely give iron sucrose in 
treatment of iron deficiency anemia. Only significant 
adverse effects reported were thrombophlebitis, rigors, 
fever and sweating which can be avoided by giving it 
slowly IV in diluted normal saline. 
Tolerabilty analysis to IV iron sucrose administration 
revealed that about 62 patients (77.5%) from total 80 
reported well tolerability while remaining 18 patients 
(22.5%) reported poor tolerability to IV Iron Sucrose. 
CONCLUSION 
Intravenous iron sucrose increases the haemoglobin 
more rapidly in first week as compared to second and 
third week in women with postpartum iron deficiency 
anemia. So, IV iron sucrose is well efficacious in the 
treatment of postpartum anemia. Hypersensitivity reac-
tion, chest pain, dyspnoea were not observed with iron 
sucrose so Iron sucrose should be considered safe treat-
ment in postpartum anemia. About 77.5% women re-
ported good tolerability to IV Iron sucrose so it should 
also be considered well tolerated option. 
Intravenous iron sucrose should be considered effica-
cious, safe and well tolerable option to fill a rift between 
blood transfusion and oral iron in treatment of postpar-
tum iron deficiency anaemia. 
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